Kayhan Moayeri’s Post

❓What would you have prescribed for this child? Would you have chosen an off-label treatment? ✍️ In treating a 10-year-old with persistent migraines, I had to balance the risks of off-label nasal sumatriptan against the potential to improve her daily life. Prescribing for children presents unique challenges, especially where there is a lack of robust evidence or suitable formulations. Collaborating with children and their families is essential for shared decision-making. 💭 This case explores my thought process and approach in navigating the complexities of prescribing for children. Let me know what you might have done. Link: https://lnkd.in/eKBmKmGF Royal Pharmaceutical Society Pharmaceutical Journal Publications NPPG Guy's and St Thomas' NHS Foundation Trust

Exciting progress in Canada to move towards the introduction of a National Pharmacare program to make prescription medications more accessible & more affordable for everyone with improved purchasing power in Canada: https://lnkd.in/g36tmMjj There are clear lessons to be learned regarding success and unintended consequences from other countries. The first phase of the Canadian plan to include prioritization for those living with diabetes is certainly required and a great start. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare: https://lnkd.in/gxntc_yc The Unintended Consequences of National Pharmacare Programs The Experiences of Australia, New Zealand, and the UK: https://lnkd.in/geFh_cnj However, there needs to be a wider lens of focus to include funding for Clinical Exercise Physiology (CEP) as Australia has shown a significant return in health system savings for every $1 invested in CEP services to help those living with chronic conditions like diabetes as determined via independent reports by Deloitte: https://lnkd.in/gwKbCfGV The benefit-cost ratio is favourable from the consumer’s perspective. For every $1 spent on patients with T2D receiving CEP interventions, they would receive $8.50 - $13.70 in wellbeing benefits, improved consumer productivity & reduced health system expenditure (2015-16 reports). The Ministry of Health In British Columbia is leading the way in Canada with plans to fund and hire Clinical Exercise Physiologists to support the needs of those living in BC: https://lnkd.in/gsARiQm2 Canadian Society for Exercise Physiology (CSEP) Société canadienne de physiologie de l’exercice SCPE looks forward to supporting this initiative in BC & working with other Provinces to create an economical and sustainable model to improve our health system from coast to coast to coast: https://lnkd.in/gec-qMX5

Medications for Canadians: Advancing Universal Access with the Pharmacare Act The Honourable Mark Holland, Minister of Health Canada | Santé Canada, and the Honourable Kamal Khera, Minister of Diversity Canada, Inclusion and Persons with Disabilities, reiterated the Government of Canada's commitment to making essential and preventive medications more accessible and affordable. In February 2024, the government introduced Bill C-64, the Pharmacare Act, marking the first phase of national universal pharmacare. This act aims to provide universal, single-payer coverage for contraceptives and diabetes medications, supporting the health of millions of Canadians. The plan includes consultations with provinces, territories, Indigenous Peoples, and other stakeholders to enhance accessibility and affordability. Additionally, the creation of the Canadian Drug Agency (CADTH), with an investment of over $89.5 million, and the National Strategy for Drugs for Rare Diseases, with up to $1.5 billion in funding, further support this effort. For more details please click the link! https://lnkd.in/deXN8Gq3 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

🗝️Unlocking the Potential of OTC Medicines: A Q&A with MAXWELLIA CEO 💊 How can pharmacies embrace over-the-counter (OTC) medicines to empower customers, reduce NHS reliance, and build a sustainable future for healthcare? Our CEO, Anna Maxwell, explores these critical questions in an exclusive interview with Pharmacy Business. The piece delves into the rising self-care revolution, the pivotal role of pharmacies in transforming healthcare access, and how MAXWELLIA is leading the charge with innovative OTC solutions like Evana® and LoviOne®. Some key insights from the article include: 🔹 90% of pharmacy income currently depends on NHS funding, an unsustainable model. Shifting to OTC medicines offers financial stability and streamlines care. 🔹 78% of adults would choose self-care first, and 3 out of - 4 adults want more OTC medicines available. This shift could save the NHS £1.7 billion annually while positioning pharmacies as trusted healthcare hubs. 🔹OTC products simplify care delivery for pharmacists—no lengthy consultations, just quick, effective solutions. At MAXWELLIA, we’re committed to making high-impact medicines available OTC, empowering pharmacies to lead this healthcare transformation. 🌟 Read the full article on pages 68–69 here: https://lnkd.in/e32UDTsN 📣 Share your thoughts: What do you think about the future of OTC medicines? #Pharmacy #OTC #HealthcareInnovation #SelfCare #Maxwellia Evana® Heavy Period Relief 500 mg tablets. Tranexamic acid. LoviOne® 1.5mg tablet. Levonorgestrel. Emergency contraception. Always read the label.

Check out the interview in Pharmacy Business with the CEO of our portfolio company MAXWELLIA - 'Unlocking the Potential of OTC Medicines: A Q&A with MAXWELLIA CEO'

Metropolis Healthcare has unveiled the results of a comprehensive three-year study aimed at enhancing #prenatal care and identifying high-risk #pregnancies more accurately. Conducted from January 2021 to December 2023, the study involved 140,528 #pregnant women and explored the efficacy of combining #Pregascreen reflex Testing with Non-invasive Prenatal Testing (NIPT) or #Karyotyping. The findings highlight the transformative impact of integrating advanced prenatal testing methods to better detect #fetal abnormalities and reduce false-positive results. The #study initially identified 5,879 pregnancies as high-risk through traditional early trimester screenings. However, by incorporating NIPT with #Pregascreen reflex testing, the accuracy of identifying genuine high-risk cases improved significantly. In the first trimester, dual marker testing initially flagged 2,416 cases as high-risk. Following NIPT reflex testing, only 64 of these cases remained classified as high-risk, while 1,142 were correctly reassigned as low risk. Similarly, in the second trimester, the Quadruple marker indicated 3,463 cases as high-risk. NIPT reflex testing then accurately reclassified 455 of these as low risk, leaving only 20 still considered high-risk. These results underscore the significant advantages of using NIPT and Pregascreen reflex testing in prenatal screening. The integration of these methods not only reduces false positives but also ensures that high-risk pregnancies are identified with greater precision. This allows healthcare providers to focus their efforts on cases that truly require intensive monitoring and intervention, ultimately improving maternal and foetal health outcomes. Dr. Sushil Shah, Chairman of Metropolis Healthcare, commented on the findings: "Our study demonstrates the critical role of advanced prenatal testing in providing accurate diagnoses and reducing unnecessary anxiety for expectant couples. By leveraging NIPT and Pregascreen reflex testing, we can offer safer, non-invasive, and highly accurate screening options that enhance prenatal care." The study highlights several benefits of this integrated approach: Enhanced Diagnostic Accuracy: By combining Pregascreen and NIPT, the precision in identifying high-risk pregnancies is significantly improved. Non-Invasive Testing: NIPT is a non-invasive procedure, eliminating the risks associated with traditional invasive tests like amniocentesis Increased Accessibility: The advanced diagnostics are made accessible to a broader range of expectant couples, promoting wider adoption and better health outcomes. Looking forward, Metropolis Healthcare is committed to expanding its services and incorporating the latest technological advancements to alleviate maternal health burdens and improve access to innovative healthcare solutions. https://lnkd.in/gsGD6vaC

🌍 Impact on Public Health: Paving the Way for Safer Pregnancies. At the LIFESAVER Project, we believe that every mother and baby deserves the highest standard of care, especially when it comes to the safety of pharmaceutical drugs during pregnancy. Our groundbreaking bio-digital placenta functionality technology is set to revolutionize the way drugs are tested for their impact on fetal development. By providing a more accurate, reliable, and ethical method of screening drugs, the bio-digital placenta can significantly reduce the risks associated with medication use during pregnancy. This means fewer adverse drug reactions, healthier pregnancies, and ultimately, better health outcomes for both mothers and their babies. The potential public health benefits are enormous. With this technology, pharmaceutical companies can ensure that their products are safer, giving healthcare providers more confidence in prescribing necessary treatments to pregnant women. This not only protects the most vulnerable but also strengthens trust in medical interventions during pregnancy. As we transition from research to commercialization, we are excited to partner with pharmaceutical companies committed to making maternal and fetal health a top priority. Together, we can create a future where every child has the best possible start in life. #LIFESAVERProject #PublicHealth #FetalSafety #MaternalHealth #InnovationInHealth #Pharmaceuticals #BioDigitalPlacenta #LIFESAVERProject #FetalSafety #PharmaEthics #DrugSafety #MaternalHealth #Pharmaceuticals #InnovationForGood #FetalHealth #DigitalTwinTechnology #HealthSafetyInnovation #LifeSaverH2020 #H2020 #EUFunded #EUHealthResearch #greendeal #HealthcareInnovation

🔦Focus this week on #diabetes and #seniors...in advance of my presentation at California Assisted Living Association. 💊All about Ozempic....and its effects on Medicare drug spending. 💰A blockbuster drug class...$5.7 billion annually in Centers for Medicare & Medicaid Services $. ⚖️But limited funds left to pay for other medicines. “These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage,” KFF Health News wrote in its analysis. Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis. The pricey medications, which include Wegovy, Mounjaro and Rybelsus, have become super popular for the treatment of diabetes and for weight loss. But Medicare is not allowed by law to cover drugs for weight loss. Ozempic ranked as the sixth top selling medication in Medicare Part D drug plans in 2022, up from 10th the prior year, according to KFF. The current list price for Ozempic is $969 for a four-week supply. #diabetes #diabetesmanagement #seniorhealth #geriatrics #geriatrichealth #mobilemedicine #housecalls American Diabetes Association FDA KFF

𝐀𝐩𝐢𝐉𝐞𝐜𝐭 𝐒𝐲𝐬𝐭𝐞𝐦𝐬 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐆𝐫𝐚𝐧𝐭 𝐭𝐨 𝐃𝐞𝐯𝐞𝐥𝐨𝐩 𝐋𝐨𝐰-𝐂𝐨𝐬𝐭 𝐁𝐥𝐨𝐰-𝐅𝐢𝐥𝐥-𝐒𝐞𝐚𝐥 𝐏𝐫𝐞𝐟𝐢𝐥𝐥𝐞𝐝 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐃𝐞𝐯𝐢𝐜𝐞 𝐟𝐨𝐫 𝐋𝐨𝐰- 𝐚𝐧𝐝 𝐌𝐢𝐝𝐝𝐥𝐞-𝐈𝐧𝐜𝐨𝐦𝐞 𝐂𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬 • Grant will fund the design and development of an affordable, multi-month contraceptive delivery device to enhance access in Low- and Middle-Income Countries (LMICs). • Blow-Fill-Seal will be explored for the container closure and subcutaneous injection delivery system, advancing a concept initially developed by ApiJect to proof-of-concept stage for cost-effective, high volume, easy to use devices for women’s reproductive health. Read Full Release: https://hubs.li/Q02VHsy10 ApiJect Systems, Corp. a public-benefit medical technology company whose device development platform will make the safety and performance advantages of single-use prefilled syringes affordable and available for many more patients in the U.S. and globally, announced today it has been awarded an initial grant of $425,000 from the Bill & Melinda Gates Foundation. The funding will support the design and development of low-cost Prefilled ApiJect Injectors for injectable medicines and vaccines, with a focus on use in LMICs. “We are honored to receive this grant from the Gates Foundation,“ said Jon Ellenthal, President, ApiJect Systems. “Our technology unlocks the many benefits of Blow-Fill-Seal manufacturing for injectable medicines to create high quality, affordable prefilled injection devices for LMICs. We will create a device that is easy to administer without the need for a medical professional and, thereby, improve access to contraceptives and other critical drugs for patients in LMIC markets. The grant will support the device development process with extensive field research in Africa.” #globalhealth #publichhealth #drugdelivery #LMICs #BFS #Grant

"Finally, we have weight-loss drugs that really work. But should older adults be taking them? Seniors hailed the recent introduction of effective weight-loss drugs to the market. Injectable semaglutide Ozempic was approved by the FDA for diabetes treatment in 2017. Weight-loss drug Wegovy, which is identical to Ozempic, was approved in 2021. Mounjaro, with active ingredient tirazepatide, got approval for diabetes in 2022. Other drugs are in development." Continue to read "Seniors and Weight-Loss Drugs" #Seniors #WeightLossDrugs #sideeffects #nausea #constipation #YourHealthMatters